{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:59:49Z","timestamp":1793638789041,"version":"4.5.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jid.2026.01.043","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:08:37Z","timestamp":1771978117000},"page":"2598-2602.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of deucravacitinib on NLR and other inflammatory biomarkers of cardiovascular risk in psoriasis: Posthoc analyses of phase 3 trials"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-5045","authenticated-orcid":false,"given":"Yi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-2726","authenticated-orcid":false,"given":"Aditi B.","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2236-698X","authenticated-orcid":false,"given":"Yevgeniy","family":"Balagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6649-3755","authenticated-orcid":false,"given":"Michael","family":"Garshick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5130","authenticated-orcid":false,"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.01.043_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jid.2026.01.043_bib2","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/jcm12175452","article-title":"Neutrophil-to-lymphocyte ratio, neutrophil-to-monocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index in psoriasis patients: response to treatment with biological drugs","volume":"12","author":"Albayrak","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jid.2026.01.043_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.01.043_bib4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamacardio.2019.2604","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: part 1, Lifestyle and behavioral factors","volume":"4","author":"Arnett","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jid.2026.01.043_bib5","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.01.043_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000545148","article-title":"Treatment of plaque psoriasis with Guselkumab reduces systemic inflammatory burden as measured by neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, and monocyte\/lymphocyte ratio: a post hoc analysis of three randomised clinical trials","volume":"241","author":"Kearney","year":"2025","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2026.01.043_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jid.2025.03.014","article-title":"Residual inflammation in patients with psoriasis treated with biologic therapy: findings from 3 prospective observational cohorts","volume":"145","author":"Lecumberri","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.01.043_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.01.043_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamadermatol.2024.4433","article-title":"Skin inflammation, systemic inflammation, and cardiovascular disease in psoriasis","volume":"161","author":"Svedbom","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.01.043_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12865-021-00454-4","article-title":"Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:32:43Z","timestamp":1793597563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022202X26001302"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.043","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of deucravacitinib on NLR and other inflammatory biomarkers of cardiovascular risk in psoriasis: Posthoc analyses of phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}